The FDA considered Pfizer’s review of sBLA in the first place

Introduction

Pfizer Inc., a popular multinational biopharmaceutical company with its origins in New York City, aims to discover appropriate vaccines and innovative drugs for immunology, inflammation, and oncology. Pfizer’s significant and most commercialised products include Advil, COVID-19 antiviral Paxlovid, Viagra and Lipitor.

Announcement

Pfizer Inc. filed for a supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) and requested priority review, as the company has to extend the qualified indication to add one treatment in line with haemophilia A or B involving individuals 6 years and older with inhibitors, and another one with the age group of 6 to 11 having no hemophilia A or B. In the U.S., the same drug has recently allowed to perform treatments for 12-year-olds and older suffering from hemophilia B, excluding factor IX (FIX) inhibitors or factor VIII (FVIII) inhibitors.

FDA’s Action

For the same sBLA review, the FDA has scheduled a Prescription Drug User Fee Act (PDUFA) action date this year (second half). Once the solution of HYMPAVZI is approved, the drug will provide a single treatment to shield the bleeding with one injection under supervision (once a week) with no much preparation or routine treatment in the lab settings. It’s an ease for the patients.

Following this and the urgency for review, FDA considered Pfizer’s request as FDA only avails the Priority Review concept to drugs that will contribute a certain advancement in treatment or be the first ever therapy to the areas where it is absent. Within four months of this request, the qualification will be granted if it meets all standards of approval.

Apart from the review, the FDA has also registered the Breakthrough Therapy Designation of HYMPAVZI for routine prophylaxis to avoid or lessen the excess amount of bleeding in individuals aged 6 to less than 12 years old having hemophilia B, regardless of inhibitors. This designation is planned to elevate the establishment and review of the drug with proven strength to promote it in the preliminary clinical evidence time where it showcases the drug’s possibility of being apt for existing treatments.

This confident submission is based on the achieved safety and efficacy results from the group that performed and contributed to the Phase 3 BASIS trial. Director, Hemostasis and Thrombosis Center at Children’s Hospital, Los Angeles, M.D., Guy Young, said, “The children population (age 6 and 11) with hemophilia A or B, will have treatment ideas which will avoid the bleeding, which is very fundamental to their growing joints.”